Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613140 · ClinicalTrials.gov registry record
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 9,230
- Enrollment target
NCT05613140: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05613140 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9,230 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05613140 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 9,230 participants
- Enrollment target
Study Summary
This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction (HFrEF) (cohort 1) and adult patients with chronic heart failure (CHF) (cohort 2).
Primary Outcome
Number of Heart Failure (HF)-specific hospitalizations was defined as the number of acute inpatient hospitalizations with a primary discharge diagnosis of HF. An acute inpatient hospitalization was defined as a medical claim for an inpatient hospitalization.
Interventions
- DRUG sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,230 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2021-11-05 |
What the finished NCT05613140 record still lists
NCT05613140 is an observational study that tracks outcomes without assigning an intervention. Its 9,230 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which sacubitril/valsartan is the first listed.
NCT05613140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05613140 about?
NCT05613140 is a clinical study titled "Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure". This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction...
What is the current status of trial NCT05613140?
This trial is currently completed. The enrollment target is 9,230 participants. The study started on 2021-08-02. Estimated completion is 2021-11-05.
What interventions are being tested in trial NCT05613140?
The interventions under investigation include: sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT05613140?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI